Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial

Abstract Background Cardiovascular disease in particular acute coronary syndrome (ACS) is remained one of the most cause of morbidity and mortality, annually. Considering inflammatory pathway of atherosclerosis, colchicine as an anti-inflammatory drug is introduced to be effective in pathogenesis, prognosis and mortality rate of these patients. So in order to find out the effects of this drug we conducted this trial to know whether it reduces major adverse cardiac events (MACE) in ACS patients or not. Methods In a prospective randomized double-blinded placebo-controlled trial, we enrolled ACS patients (40–70 years) with recent ST-segment elevation myocardial infarction (STEMI) or NSTE-ACS diagnosed by coronary angiography and managed with either medical therapy or percutaneous coronary intervention. Patients were assigned to two groups either receiving colchicine 0.5 mg daily or placebo for 6 months. Both groups simultaneously received standard medical therapy as accessible guidelines. MACE occurrence consists of decompensated heart failure, ACS, stroke and survival rate compared between two groups. Results A total of 249 patients were recruited between October 2019-March 2020 with mean age of 56.89 ± 7.54, 69.5% males; 120 assigned to the colchicine group and 129 assigned to the placebo group. Over the 6 months’ period, 36 MACE occurred that were 8 events in the colchicine group compared with 28 events in the placebo group experiencing the event (P = 0.001). All of four deaths in the colchicine group and two in the placebo group were due to cardiovascular events. Evaluating adverse effects, gastrointestinal symptom was the most with the rate of 15 (12.5%) in the colchicine group and 3 (2.5%) in the controls. (P = 0.002). Conclusion The addition of colchicine to standard medical therapy in ACS patients significantly reduces MACE occurrence and improves survival rate over the time.

Download Full-text

Diagnosis of acute coronary syndrome in the emergency room: the dictatorship of high-sensitivity cardiac troponin and major adverse cardiac events

European Journal of Emergency Medicine ◽

10.1097/mej.0000000000000733 ◽

2020 ◽

Vol 27 (4) ◽

pp. 239-240

Author(s):

Pierre Hausfater ◽

Laetitia Velly

Keyword(s):

Acute Coronary Syndrome ◽

Emergency Room ◽

Cardiac Troponin ◽

High Sensitivity ◽

Major Adverse Cardiac Events ◽

Cardiac Events ◽

Coronary Syndrome ◽

Adverse Cardiac Events

Download Full-text

Predicting the Occurrence of Major Adverse Cardiac Events in Patients with Acute Coronary Syndrome Using Synthetic Minority Oversampling Technique and Machine Learning Approach

Advances in Intelligent Information Hiding and Multimedia Signal Processing - Smart Innovation, Systems and Technologies ◽

10.1007/978-981-33-6757-9_19 ◽

2021 ◽

pp. 140-148

Author(s):

Huilin Zheng ◽

Batireedui Baterdene ◽

Jong Yun Lee

Keyword(s):

Machine Learning ◽

Acute Coronary Syndrome ◽

Major Adverse Cardiac Events ◽

Learning Approach ◽

Cardiac Events ◽

Coronary Syndrome ◽

Adverse Cardiac Events ◽

Machine Learning Approach

Download Full-text

A Meta-analysis of 64-section Coronary CT Angiography Findings for Predicting 30-day Major Adverse Cardiac Events in Patients Presenting with Symptoms Suggestive of Acute Coronary Syndrome

Academic Radiology ◽

10.1016/j.acra.2011.08.013 ◽

2011 ◽

Vol 18 (12) ◽

pp. 1522-1528 ◽

Cited By ~ 23

Author(s):

Kevin M. Takakuwa ◽

Scott W. Keith ◽

Adrian T. Estepa ◽

Frances S. Shofer

Keyword(s):

Acute Coronary Syndrome ◽

Ct Angiography ◽

Coronary Ct Angiography ◽

Meta Analysis ◽

Major Adverse Cardiac Events ◽

Cardiac Events ◽

Coronary Syndrome ◽

Coronary Ct ◽

Adverse Cardiac Events

Download Full-text

Diagnostic and prognostic impact of circulating microRNA-208b and microRNA-499 in patients with acute coronary syndrome

Biomarkers in Medicine ◽

10.2217/bmm-2019-0257 ◽

2020 ◽

Vol 14 (2) ◽

pp. 87-95

Author(s):

Wei Wang ◽

Tai Li ◽

Lei Gao ◽

Yang Li ◽

Ying Sun ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Proportional Hazards ◽

Cox Proportional Hazards ◽

Major Adverse Cardiac Events ◽

Circulating Microrna ◽

Prognostic Impact ◽

Cardiac Events ◽

Primary Analysis ◽

Coronary Syndrome ◽

Adverse Cardiac Events

Aim: This study aimed to investigate the correlation between the expression of circulating miR-208b and miR-499 and acute coronary syndrome (ACS) patients. Materials & methods: A total of 160 consecutive patients with ACS and 48 healthy control subjects were enrolled for primary analysis. The ACS patients (n = 160) were followed up for 6 months for further analysis regarding major adverse cardiac events. Results: Area under the curve values of miR-208b and miR-499 for predicting ACS were 0.910 and 0.851 (p < 0.001, respectively). Cox proportional hazards regression analysis revealed that miR-208b but not miR-499 was an independent predictor of major adverse cardiac events. Conclusion: Circulating miR-208b and miR-499 could be considered as diagnostic or prognostic biomarkers for patients with ACS.

Download Full-text

Comment on Gerbaud et al. Glycemic Variability Is a Powerful Independent Predictive Factor of Midterm Major Adverse Cardiac Events in Patients With Diabetes With Acute Coronary Syndrome. Diabetes Care 2019;42:674–681

Diabetes Care ◽

10.2337/dc19-1159 ◽

2019 ◽

Vol 42 (10) ◽

pp. e168-e169

Author(s):

You Yang ◽

Yunzhao Hu

Keyword(s):

Acute Coronary Syndrome ◽

Predictive Factor ◽

Diabetes Care ◽

Glycemic Variability ◽

Major Adverse Cardiac Events ◽

Cardiac Events ◽

Independent Predictive Factor ◽

Coronary Syndrome ◽

Adverse Cardiac Events ◽

Patients With Diabetes

Download Full-text

Glycemic Variability Is a Powerful Independent Predictive Factor of Midterm Major Adverse Cardiac Events in Patients With Diabetes With Acute Coronary Syndrome

Diabetes Care ◽

10.2337/dc18-2047 ◽

2019 ◽

Vol 42 (4) ◽

pp. 674-681 ◽

Cited By ~ 26

Author(s):

Edouard Gerbaud ◽

Romain Darier ◽

Michel Montaudon ◽

Marie-Christine Beauvieux ◽

Christine Coffin-Boutreux ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Predictive Factor ◽

Glycemic Variability ◽

Major Adverse Cardiac Events ◽

Cardiac Events ◽

Independent Predictive Factor ◽

Coronary Syndrome ◽

Adverse Cardiac Events ◽

Patients With Diabetes

Download Full-text

Referral decisions based on a prehospital HEART score in suspected non-ST-elevation acute coronary syndrome: design of the FamouS Triage 3 study

Future Cardiology ◽

10.2217/fca-2019-0030 ◽

2020 ◽

Vol 16 (4) ◽

pp. 217-226

Author(s):

Dominique N van Dongen ◽

Rudolf T Tolsma ◽

Marion J Fokkert ◽

Erik A Badings ◽

Aize van der Sluis ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Risk Stratification ◽

Major Adverse Cardiac Events ◽

Cardiac Events ◽

Heart Score ◽

Coronary Syndrome ◽

Referral Decisions ◽

Adverse Cardiac Events ◽

St Elevation ◽

Elevation Acute Coronary Syndrome

Background: It is not yet investigated whether referral decisions based on prehospital risk stratification of non-ST-elevation Acute Coronary Syndrome (NSTE-ACS) by the complete History, ECG, Age, Risk factors and initial Troponin (HEART) score are feasible and safe. Hypothesis: Implementation of referral decisions based on the prehospital acquired HEART score in patients with suspected NSTE-ACS is feasible and not inferior to routine management in the occurrence of major adverse cardiac events within 45 days. Study design & methods: FamouS Triage 3 is a feasibility study with a before–after sequential design. The aim is to assess whether prehospital HEART-score management including point-of-care troponin measurement is feasible and noninferior to routine management. Primary end point is the occurrence of major adverse cardiac events within 45 days. Conclusion: If referral decisions based on prehospital acquired risk stratification are feasible and noninferior this can become the new prehospital management in suspected NSTE-ACS.

Download Full-text